ANTIVIRAL RESEARCH抗病毒研究
ANTIVIRAL RESEARCH(英文缩写 ANTIVIR RES),ISSN 0166-3542,eISSN 1872-9096,中文译名:抗病毒研究 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 10.103 | Q1 |
| 2022 | 7.600 | Q1 |
| 2023 | 4.500 | Q1 |
| 2024 | 4.000 | Q1 |
| 2025 | 4.300 | Q1 |
ANTIVIRAL RESEARCH 最新收录文献
-
1. About artificial intelligence adoption in antiviral drug discovery: Thoughts after ICAR 39.
PMID:日期:2026-09-23Artificial intelligence (AI) is increasingly discussed across biomedical research, yet its adoption in antiviral drug discovery remains modest. This is paradoxical because antiviral research urgently needs precisely what AI can provide: faster target prioritization, more effective reuse of fragmented datasets, rapid drug repurposing, de novo molecular design and early resistance prediction. Limited adoption, however, does not simply reflect conservatism. Antiviral datasets are frequently small, heterogeneous, and assay-dependent; many models are difficult to interpret; and a substantial part of the literature still relies on docking scores or retrospective benchmarks rather than prospective biological validation. Skepticism among virologists, medicinal chemists, and pharmacologists is therefore understandable, but it should be directed at poorly designed workflows rather than at AI methods themselves. These limitations are not uniform across methods: supervised activity models are constrained mainly by data, generative models by how their objectives are specified, and general-purpose foundation models by domain mismatch and evaluation design, so each requires a different remedy. The field can advance by building curated antiviral datasets with standardized metadata, deploying interpretable and uncertainty-aware models, filtering predictions by pharmacological feasibility, and embedding AI within iterative computation-experiment loops. Sustained investment in training schools, hands-on workshops, and shared benchmark challenges will be essential if AI is to become a routine and trusted component of antiviral discovery.
-
2. A self-adjuvant trivalent T4 bacteriophage nanoparticle vaccine induces broad protective immunity against Orthoebolaviruses.
PMID:日期:2026-09-21Orthoebolaviruses, including Zaire virus, Sudan virus, and Bundibugyo virus, remain major public health threats because of their high case-fatality rates and recurrent outbreaks. Although licensed vaccines provide effective protection against EBOV, broadly protective vaccines against multiple pathogenic orthoebolavirus species remain unavailable. Here, we developed T4 bacteriophage-based nanoparticle vaccines displaying glycoproteins (GPs) from EBOV, SUDV, and BDBV by leveraging the SpyTag/SpyCatcher conjugation system. Monovalent vaccine candidates and a trivalent formulation (T4-Mix) were generated to evaluate their potential for broad orthoebolavirus immunization. Intramuscular immunization of BALB/c mice elicited robust GP-specific humoral and cellular immune responses without the need for exogenous adjuvants. In homologous surrogate challenge models using replication-competent recombinant vesicular stomatitis viruses expressing EBOV, SUDV, or BDBV GP, all monovalent vaccines conferred complete protection against their respective challenge viruses. Furthermore, the optimized trivalent T4-Mix formulation provided complete protection against rVSV-EBOV, rVSV-SUDV, and rVSV-BDBV challenges. Collectively, these findings demonstrate that the T4 bacteriophage functions as both an antigen delivery vehicle and an intrinsic immunostimulatory scaffold, highlighting its potential as a versatile platform for the development of broadly protective multivalent orthoebolavirus vaccines.
-
3. 4-octyl itaconate inhibits porcine epidemic diarrhea virus replication by modulating the ferroptosis axis and the autophagy pathway.
PMID:日期:2026-09-18Porcine epidemic diarrhea virus (PEDV) continues to pose a significant threat to the swine industry, leading to high mortality in neonatal piglets and substantial economic losses. The emergence of antigenic variants often compromises vaccine efficacy, highlighting the need for novel antiviral strategies. This study investigates the potential of 4-octyl itaconate (4-OI) as a novel therapeutic agent against PEDV. In vitro studies demonstrated that 4-OI exhibited dose-dependent antiviral activity across multiple cell lines, directly reduced viral infectivity, and displayed broad-spectrum inhibitory effects against enveloped viruses. In a piglet model, 4-OI administration (100 mg/kg) significantly reduced disease severity, as evidenced by decreased intestinal viral load and tissue damage, improved weight gain, reduced diarrhea, and enhanced survival. Mechanistically, 4-OI inhibits PEDV replication by modulating ferroptosis and autophagy pathways, thereby restricting viral exploitation of host autophagy-ferroptosis crosstalk. These findings suggest that 4-OI is a promising therapeutic candidate for PEDV infection, offering a novel host-targeted antiviral approach and opening up a promising new direction for antiviral therapy.
-
4. Low level drug resistance linked to cytomegalovirus UL97 and UL27 mutations detected in maribavir clinical trials.
PMID:日期:2026-09-16Cytomegalovirus genetic variants of indeterminate significance reported as supplementary findings in two Phase 3 maribavir clinical trials were evaluated for their effects on antiviral drug susceptibility after transfer into baseline viral strains. Among 8 UL97 kinase variants tested, none were found to confer maribavir resistance, while amino acid substitution G598A conferred borderline ganciclovir resistance (1.9-fold increased 50% effective concentration [EC50]) and K599N did not (1.1-fold). These codons do not appear to be important loci of resistance substitutions as compared with others in the 590-607 range, such as C592G, A594V, L595S/F and C603W. Among 3 new UL27 variants tested, L317V was found to confer 2-fold increased maribavir EC50, the same increase as a previously published UL27 L193F. Both resistant UL27 mutants were observed in connection with maribavir treatment failure, but L317V differs in being detected as an emergent mutation after 29 days of therapy rather than at baseline. The clinical significance of baseline and emergent UL27 mutations for maribavir therapy requires further surveillance.
-
5. Monoclonal antibodies targeting HBsAg as anti-HDV: clinical prospects.
PMID:日期:2026-09-15Hepatitis D (delta) virus (HDV) remains the most severe form of chronic viral hepatitis and represents a substantial global health burden. Although effective prophylactic vaccines against hepatitis B virus (HBV) indirectly prevent HDV infection, an estimated 12 million people worldwide remain chronically infected with HDV. Current antiviral strategies suppress viral replication but rarely achieve sustained virological response or functional cure, resulting in lifelong treatment for many patients. As HDV depends on hepatitis B surface antigen (HBsAg) for virion assembly and entry into hepatocytes, targeting the viral envelope represents an attractive therapeutic strategy to prevent viral spread. Advances in recombinant antibody engineering have enabled the development of highly potent human monoclonal antibodies (mAbs) against viral pathogens, including HBV and HDV. Neutralizing anti-HBsAg mAbs block viral entry by binding HBsAg and preventing its interaction with the receptor, while their Fc domains may additionally promote immune-mediated clearance of viral particles and infected cells. Compared with conventional small-molecule antivirals, mAbs generally exhibit high target specificity and favorable safety profiles, thus making them promising candidates for antiviral therapy. Currently, one mAb has been licensed in China for the treatment of adults with chronic HDV, with or without compensated cirrhosis, while several additional neutralizing mAbs are being evaluated in preclinical and clinical studies as monotherapy or in combination with other antiviral agents. This review summarizes the current landscape of monoclonal antibody development for chronic HDV infection, highlighting their mechanisms of action, preclinical and clinical efficacy, and potential role in future therapeutic strategies.
-
6. Marine phlorotannins block SARS-CoV-2 entry via ACE2 and attenuate pulmonary inflammation in K18-hACE2 transgenic mice.
PMID:日期:2026-09-15SARS-CoV-2 has transitioned from pandemic to endemic circulation, yet it continues to cause severe respiratory disease, particularly in vulnerable populations. Effective antivirals with well-defined mechanisms of action remain a critical unmet need. Marine phlorotannins are structurally complex polyphenols from edible brown seaweeds with established antiviral and anti-inflammatory properties, making them promising candidates for therapeutic development. Our previous work demonstrated that selected phlorotannins suppress SARS-CoV-2 replication through inhibition of the viral proteases 3C-like protease (3CL) and papain-like protease (PL). The present study extended this work by investigating whether these compounds could also block viral entry via the angiotensin-converting enzyme-2 (ACE2) receptor. Molecular docking of 16 phlorotannins against ACE2 revealed strong binding affinities for Ishophloroglucin A (IPA), diphlorethohydroxycarmalol (DPHC), and eckmaxol, isolated from Ishige okamurae and Ecklonia cava. In vitro assays confirmed that all three compounds dose-dependently inhibited ACE2 and spike receptor-binding domain (RBD) interaction and blocked SARS-CoV-2 pseudovirus entry into HEK293T-ACE2 cells. Based on its favorable pharmacokinetic profile, DPHC was selected for in vivo evaluation in K18-hACE2 transgenic mice infected with live SARS-CoV-2. DPHC administration at 25 and 50 mg/kg dose-dependently reduced pulmonary viral titers, suppressed nucleocapsid gene expression, and alleviated histopathological lung injury. It also selectively downregulated the pro-inflammatory mediators interferon-gamma (IFN-γ) and monocyte chemoattractant protein-1 (MCP-1), with high-dose efficacy comparable to remdesivir. These findings identify DPHC as a well-characterized phytochemical with integrated antiviral and immunomodulatory activity, targeting viral entry, replication, and inflammation through a multi-target mechanism.
-
7. Identification of 1,2-dihydroquinazolin-2-ones kinase inhibitors as anti-coronavirus agents.
PMID:日期:2026-09-15The growing threat of viral pandemics, along with the emergence and re-emergence of various viruses, highlights an urgent need for innovative antiviral strategies. Traditional antivirals typically target viral proteins, but this approach often faces challenges like drug resistance and specificity. In contrast, host-based antivirals present a promising alternative by focusing on cellular factors essential for viral replication, which can potentially limit viral adaptation and resistance. Kinase inhibitors are a notable class within these therapies, as viruses frequently exploit kinases to aid in their replication, making them a crucial therapeutic target. By blocking these signalling pathways, kinase inhibitors can disrupt viral replication, broadening their range of use and providing effective defences against multiple pathogens. To search for effective inhibitory agents, we performed a high-content screening (HCS) of a 406-compound library of kinase inhibitor chemotypes using human coronavirus OC43 (HCoV-OC43). The compounds were selected based on their favourable cytotoxicity profile from a larger kinase library. In the primary screen, 57 hits were identified that belong to 9 chemical families. Of these, dose response analysis distinguished 20 compounds that exhibited EC < 10 μM. Four compounds with EC < 3 μM and favourable selectivity belong to a series of 1,2-dihydroquinazolin-2-ones, representing a novel class of antivirals.
-
8. Remdesivir maintains antiviral potency against clinically relevant SARS-CoV-2 Nsp12 substitutions.
PMID:日期:2026-09-14Remdesivir (RDV) is a nucleotide analog prodrug approved for COVID-19 treatment that inhibits the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp; nsp12). Although RDV maintains activity against circulating variants of concern, ongoing evaluation of resistance-associated substitutions is critical for clinical care, particularly in settings of prolonged viral replication such as immunocompromised individuals. We assessed the phenotypic impact of nsp12 substitutions identified from in vitro resistance selection, RDV clinical reports, and global sequence surveillance. Using a recombinant infectious SARS-CoV-2 reporter virus, we compared susceptibility of these nsp12 substitutions to RDV and its parent nucleoside, GS-441524. After confirming concordant resistance profiles between RDV and GS-441524, we assessed RDV susceptibility in a complementary non-infectious replicon system. In both systems, single nsp12 substitutions remained fully susceptible to RDV within their respective assay variability limits. Of the double substitutions tested, S759A/V792I conferred the largest reduction in antiviral susceptibility (∼15-fold) but was associated with impaired replication kinetics. Given the strong concordance between the two assays, the replicon system also enabled phenotypic characterization of substitutions E802A, E802D, and P323L/E802D that could not be rescued as infectious virus. Analysis of >17 million SARS-CoV-2 genomes in GISAID showed that all tested nsp12 substitutions had low prevalence (≤0.1%), except P323L (98.8%). Collectively, these data reinforce the high genetic barrier to RDV resistance, as reduced susceptibility is typically accompanied by substantial reductions in replication. Our findings support the continued clinical utility of RDV and highlight the complementary value of SARS-CoV-2 infectious virus and replicon systems for antiviral resistance surveillance and phenotyping.
-
9. Application of emerging technologies in the antiviral field.
9. 新兴技术在抗病毒领域的应用PMID:日期:2026-09-05Viral diseases pose a serious threat to global public health, agriculture, and biosecurity. Conventional antiviral strategies are often limited by an incomplete understanding of disease mechanisms, poor targeting precision, and slow response times. Emerging technologies are now reshaping the landscape of antiviral research. This review examines the roles of four key frontiers, including organoid models, gene editing, AI-driven molecular design, and synthetic biology. Organoids provide physiologically relevant platforms that model virus-host interactions and disease progression. Viral infections remain a major challenge to human and animal health, agriculture, and biosecurity. Progress in antiviral research is constrained by the complexity of viral pathogenesis, the diversity and rapid evolution of viruses, and the limited translational relevance of some traditional model systems. Recent advances in organoid technology, gene editing, artificial intelligence, and synthetic biology are expanding the toolkit available for antiviral research and development. In this review, we discuss how these four technological frontiers contribute to disease modeling, target discovery, molecular design, and translational innovation. Organoids, in particular, provide physiologically relevant systems for investigating viral infection, tissue tropism, host responses, and pathogenesis. Gene editing tools, such as CRISPR, enable precise manipulation of host and viral genomes, facilitating the development of resistant organisms and next-generation vaccine platforms. AI technologies, including AlphaFold for structure prediction and platforms for de novo protein design, address long-standing bottlenecks in structural biology and offer powerful means to engineer antiviral proteins, antibodies, and vaccine antigens. Synthetic biology, guided by the Design-Build-Test-Learn cycle, integrates computational design, genetic assembly, and functional validation into a cohesive pipeline. Together, these technologies form a synergistic workflow that spans disease modeling, target discovery, molecular design, construction, testing, and iterative optimization. This integrated approach is shifting antiviral development from traditional empirical methods toward more precise, intelligent strategies. The review also highlights ongoing challenges in integration and scalability, stressing that high-quality biological datasets and stronger interdisciplinary collaboration are essential for realizing translational potential. By presenting a cohesive view of these converging methodologies, this review offers a framework to guide the intelligent evolution of antiviral strategies in both human and animal health.
-
10. High-yield production of immunogenic PV3 virus-like particle in yeast.
PMID:日期:2026-09-04The identification of thermally stabilized mutants of all three poliovirus serotypes (PV1, PV2, and PV3) has enabled the development of virus-like particle (VLP)-based next-generation poliovirus vaccines. PV3 stabilized mutant-derived VLPs (sVLPs) have been produced in several recombinant systems through co-expression of mutant P1 polyprotein with native or uncleavable viral protease 3CD, and have shown immunogenicity in animal models. However, their yields remain suboptimal, likely because of intrinsic 3CD toxicity and/or inefficient 3CD-mediated cleavage of P1 into capsid subunits VP0, VP3, and VP1, creating a bottleneck for cost-effective product development. In this study, we designed a protease-independent expression strategy based on simultaneous co-expression of VP0, VP3, and VP1 capsid subunit (VP0/VP3/VP1) and compared it with the conventional P1/3CD co-expression approach for production of PV3 sVLP and wildtype VLP (wtVLP) in Pichia pastoris. For each VLP type, the VP0/VP3/VP1 strategy in general enhances target protein expression and D-antigen formation compared with P1/3CD co-expression. The PV3 sVLP produced by the VP0/VP3/VP1 strategy possesses higher levels of D-antigen and significantly enhanced thermostability than the corresponding wtVLP. Moreover, structural and immunological analyses reveal that PV3 sVLP, but not wtVLP, adopts a native conformation and potently elicits neutralizing antibodies in a mouse model. These findings not only confirm yeast-produced PV3 sVLP as a promising vaccine candidate, but also establish a high-yield and scalable expression strategy amenable to further development and industrial-level production of sVLP-based next-generation polio vaccines.